<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rizzo, Toni</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Leon, Martin B.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Tryton Two-Stent Strategy Safe, but Did Not Meet Noninferiority Endpoint</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">20-21</style></pages><abstract><style  face="normal" font="default" size="100%">The current recommended treatment for patients with coronary bifurcation lesions is main branch stenting with provisional side branch stenting. This approach can lead to suboptimal results in the side branch of true bifurcation lesions, in which disease affects the origin of both branches. The objective of the Prospective Single Blind, Randomized Controlled Study to Evaluate the Safety &amp; Effectiveness of the Tryton Side Branch Stent Used With DES in Treatment of de Novo Bifurcation Lesions in the Main Branch &amp; Side Branch in Native Coronaries [TRYTON; NCT01258972] was to compare clinical and angiographic outcomes of the provisional one-stent strategy with the Tryton bifurcation two-stent approach in patients with true bifurcation lesions.</style></abstract><number><style face="normal" font="default" size="100%">19</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>